Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| HTS_TST |
25-29, Female, Negative |
2019 |
102,161 |
| HTS_TST |
25-29, Female, Negative |
2019 |
66,576 |
| HTS_TST |
25-29, Male, Negative |
2019 |
66,226 |
| HTS_TST |
30-34, Female, Negative |
2019 |
37,835 |
| HTS_TST |
30-34, Female, Negative |
2019 |
135,896 |
| HTS_TST |
30-34, Male, Negative |
2019 |
114,140 |
| HTS_TST |
35-39, Female, Negative |
2019 |
18,583 |
| HTS_TST |
35-39, Female, Negative |
2019 |
128,982 |
| HTS_TST |
35-39, Male, Negative |
2019 |
139,919 |
| HTS_TST |
40-49, Female, Negative |
2019 |
6,668 |
| HTS_TST |
40-49, Female, Negative |
2019 |
210,696 |
| HTS_TST |
40-49, Male, Negative |
2019 |
299,079 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2019 |
2,128,801 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 10-14, Negative |
2019 |
346 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 15-19, Negative |
2019 |
10,926 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 20-24, Negative |
2019 |
47,197 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 50+, Negative |
2019 |
196 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 1-9, Negative |
2019 |
51 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative |
2019 |
12 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative |
2019 |
12 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 1-9, Negative |
2019 |
51,625 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative |
2019 |
12,148 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative |
2019 |
12,148 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative |
2019 |
76,022 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative |
2019 |
42,745 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative |
2019 |
251,472 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative |
2019 |
34,657 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative |
2019 |
48,311 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative |
2019 |
66,614 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
6,626 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
6,660 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
4,515 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
5,172 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
8,890 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
7,496 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
2,438 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
8,485 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
9,670 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
657 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
1 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
13,750 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
19,714 |
| HTS_TST_POS |
Service Delivery Point (Facility) ANC: 10-14, Positive |
2019 |
113 |
| HTS_TST_POS |
Service Delivery Point (Facility) ANC: 15-19, Positive |
2019 |
2,304 |
| HTS_TST_POS |
Service Delivery Point (Facility) ANC: 20-24, Positive |
2019 |
6,438 |
| HTS_TST_POS |
Service Delivery Point (Facility) ANC: 50+, Positive |
2019 |
82 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 1-9, Positive |
2019 |
4,217 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive |
2019 |
2,320 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive |
2019 |
1,896 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive |
2019 |
5,098 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive |
2019 |
2,749 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive |
2019 |
17,689 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive |
2019 |
2,707 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive |
2019 |
3,279 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive |
2019 |
4,590 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 20-24, Female, Positive |
2019 |
1 |
| PMTCT_ART |
Already on ART at beginning of current pregnancy |
2019 |
25,537 |
| PMTCT_ART |
New on ART |
2019 |
29,340 |
| PMTCT_ART |
Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy |
2019 |
54,877 |
| PMTCT_ART |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2019 |
244,413 |
| PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2019 |
50,610 |
| PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2019 |
2,665 |
| PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2019 |
53,275 |
| PMTCT_EID |
Sum of Infant Age disaggregates |
2019 |
53,275 |
| PMTCT_STAT |
25-29, Female |
2019 |
82,827 |
| PMTCT_STAT |
25-29, Female, Known at Entry Positive |
2019 |
9,658 |
| PMTCT_STAT |
25-29, Female, Newly Identified Negative |
2019 |
66,567 |
| PMTCT_STAT |
25-29, Female, Newly Identified Positive |
2019 |
6,591 |
| PMTCT_STAT |
30-34, Female |
2019 |
50,500 |
| PMTCT_STAT |
30-34, Female, Known at Entry Positive |
2019 |
7,463 |
| PMTCT_STAT |
30-34, Female, Newly Identified Negative |
2019 |
37,808 |
| PMTCT_STAT |
30-34, Female, Newly Identified Positive |
2019 |
5,150 |
| PMTCT_STAT |
35-39, Female |
2019 |
24,418 |
| PMTCT_STAT |
35-39, Female, Known at Entry Positive |
2019 |
3,390 |
| PMTCT_STAT |
35-39, Female, Newly Identified Negative |
2019 |
18,580 |
| PMTCT_STAT |
35-39, Female, Newly Identified Positive |
2019 |
2,416 |
| PMTCT_STAT |
40-49, Female |
2019 |
8,250 |
| PMTCT_STAT |
40-49, Female, Known at Entry Positive |
2019 |
862 |
| PMTCT_STAT |
40-49, Female, Newly Identified Negative |
2019 |
6,679 |
| PMTCT_STAT |
40-49, Female, Newly Identified Positive |
2019 |
585 |
| PMTCT_STAT |
By Age (Numerator): : 15-19 |
2019 |
15,449 |
| PMTCT_STAT |
By Age (Numerator): 10-14 |
2019 |
646 |
| PMTCT_STAT |
By Age (Numerator): 20-24 |
2019 |
62,011 |
| PMTCT_STAT |
By Age (Numerator): 50+ |
2019 |
330 |
| PMTCT_STAT |
By known positives: 10-14 |
2019 |
154 |
| PMTCT_STAT |
By known positives: 15-19 |
2019 |
2,184 |
| PMTCT_STAT |
By known positives: 20-24 |
2019 |
8,357 |
| PMTCT_STAT |
By known positives: 50+ |
2019 |
8 |
| PMTCT_STAT |
By new negatives: 10-14 |
2019 |
305 |
| PMTCT_STAT |
By new negatives: 15-19 |
2019 |
10,928 |
| PMTCT_STAT |
By new negatives: 20-24 |
2019 |
47,201 |
| PMTCT_STAT |
By new negatives: 50+ |
2019 |
182 |
| PMTCT_STAT |
By new positives: 10-14 |
2019 |
113 |
| PMTCT_STAT |
By new positives: 15-19 |
2019 |
2,276 |
| PMTCT_STAT |
By new positives: 20-24 |
2019 |
6,441 |
| PMTCT_STAT |
By new positives: 50+ |
2019 |
80 |
| PMTCT_STAT |
Number of new ANC and L&D clients |
2019 |
246,831 |
| PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2019 |
244,413 |
| PMTCT_STAT_den |
25-29, Female |
2019 |
78,808 |
| PMTCT_STAT_den |
30-34, Female |
2019 |
50,544 |
| PMTCT_STAT_den |
35-39, Female |
2019 |
24,504 |
| PMTCT_STAT_den |
40-49, Female |
2019 |
7,816 |
| PMTCT_STAT_den |
By Age (Denominator): 10-14 |
2019 |
1,253 |
| PMTCT_STAT_den |
By Age (Denominator): 15-19 |
2019 |
19,839 |
| PMTCT_STAT_den |
By Age (Denominator): 20-24 |
2019 |
63,361 |
| PMTCT_STAT_den |
By Age (Denominator): 50+ |
2019 |
706 |
| TB_STAT |
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
6 |
| TB_STAT |
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
6 |
| TB_STAT |
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period |
2019 |
12 |
| TB_STAT |
Total number of registered new and relapsed TB cases, during the reporting period |
2019 |
12 |
| TB_STAT_den |
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
6 |
| TB_STAT_den |
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
6 |
| TX_CURR |
25-29, Female, Positive |
2019 |
80,094 |
| TX_CURR |
25-29, Male, Positive |
2019 |
30,212 |
| TX_CURR |
30-34, Female, Positive |
2019 |
103,623 |
| TX_CURR |
30-34, Male, Positive |
2019 |
64,326 |
| TX_CURR |
35-39, Female, Positive |
2019 |
107,880 |
| TX_CURR |
35-39, Male, Positive |
2019 |
72,772 |
| TX_CURR |
40-49, Female, Positive |
2019 |
154,719 |
| TX_CURR |
40-49, Male, Positive |
2019 |
124,915 |
| TX_CURR |
Age/Sex: <1 |
2019 |
1,890 |
| TX_CURR |
Age/Sex: 1-9 |
2019 |
20,481 |
| TX_CURR |
Age/Sex: 10-14 Female |
2019 |
12,114 |
| TX_CURR |
Age/Sex: 10-14 Male |
2019 |
9,273 |
| TX_CURR |
Age/Sex: 15-19 Female |
2019 |
25,011 |
| TX_CURR |
Age/Sex: 15-19 Male |
2019 |
9,588 |
| TX_CURR |
Age/Sex: 20-24 Female |
2019 |
79,662 |
| TX_CURR |
Age/Sex: 20-24 Male |
2019 |
16,319 |
| TX_CURR |
Age/Sex: 50+ Female |
2019 |
48,591 |
| TX_CURR |
Age/Sex: 50+ Male |
2019 |
37,218 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
998,688 |
| TX_CURR |
Sum of Age/Sex disaggregations |
2019 |
34,599 |
| TX_NEW |
25-29, Female, Positive |
2019 |
7,857 |
| TX_NEW |
25-29, Male, Positive |
2019 |
5,503 |
| TX_NEW |
30-34, Female, Positive |
2019 |
10,164 |
| TX_NEW |
30-34, Male, Positive |
2019 |
9,212 |
| TX_NEW |
35-39, Female, Positive |
2019 |
11,091 |
| TX_NEW |
35-39, Male, Positive |
2019 |
13,122 |
| TX_NEW |
40-49, Female, Positive |
2019 |
17,315 |
| TX_NEW |
40-49, Male, Positive |
2019 |
22,672 |
| TX_NEW |
By Age/Sex: <1 |
2019 |
11 |
| TX_NEW |
By Age/Sex: 1-9 |
2019 |
3,793 |
| TX_NEW |
By Age/Sex: 10-14 Female |
2019 |
2,086 |
| TX_NEW |
By Age/Sex: 10-14 Male |
2019 |
1,709 |
| TX_NEW |
By Age/Sex: 15-19 Female |
2019 |
5,901 |
| TX_NEW |
By Age/Sex: 15-19 Male |
2019 |
3,381 |
| TX_NEW |
By Age/Sex: 20-24 Female |
2019 |
20,260 |
| TX_NEW |
By Age/Sex: 20-24 Male |
2019 |
3,939 |
| TX_NEW |
By Age/Sex: 50+ Female |
2019 |
4,035 |
| TX_NEW |
By Age/Sex: 50+ Male |
2019 |
5,800 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
147,852 |
| TX_NEW |
Sum of Age/Sex disaggregates |
2019 |
47,111 |
